CliffBio

Bioverativ

Patent cliffs & loss of exclusivity

Bioverativ is a global biotechnology company developing therapies for hemophilia and other rare blood disorders, including sickle cell disease and beta-thalassemia.

Company

CAGE Code7WTM8
Company Operating StatusActive
Full Address225 2nd Ave, Waltham, MA 02451, US
LinkedIn URLhttps://www.linkedin.com/company/bioverativ/
Pitchbook URLhttps://pitchbook.com/profiles/company/169838-02
Public/PrivatePublic
Official Websitehttp://bioverativ.com
Wikidata IDQ28155329

12 upcoming patent cliffs

DrugIngredientTypeCliff
  1. AlprolixCoagulation Factor IX (Recombinant), Fc Fusion ProteinBiologicMar 2026
  2. AlprolixCoagulation Factor IX (Recombinant), Fc Fusion ProteinBiologicMar 2026
  3. AlprolixCoagulation Factor IX (Recombinant), Fc Fusion ProteinBiologicMar 2026
  4. AlprolixCoagulation Factor IX (Recombinant), Fc Fusion ProteinBiologicMar 2026
  5. EloctateAntihemophilic Factor (Recombinant), Fc Fusion proteinBiologicJun 2026
  6. EloctateAntihemophilic Factor (Recombinant), Fc Fusion proteinBiologicJun 2026
  7. EloctateAntihemophilic Factor (Recombinant), Fc Fusion proteinBiologicJun 2026
  8. EloctateAntihemophilic Factor (Recombinant), Fc Fusion proteinBiologicJun 2026
  9. EloctateAntihemophilic Factor (Recombinant), Fc Fusion proteinBiologicJun 2026
  10. EloctateAntihemophilic Factor (Recombinant), Fc Fusion proteinBiologicJun 2026
  11. EloctateAntihemophilic Factor (Recombinant), Fc Fusion proteinBiologicJun 2026
  12. AlprolixCoagulation Factor IX (Recombinant), Fc Fusion ProteinBiologicFeb 2028
  13. AlprolixCoagulation Factor IX (Recombinant), Fc Fusion ProteinBiologicJul 2028
  14. EloctateAntihemophilic Factor (Recombinant), Fc Fusion proteinBiologicJan 2029
  15. EloctateAntihemophilic Factor (Recombinant), Fc Fusion proteinBiologicJan 2029
  16. EloctateAntihemophilic Factor (Recombinant), Fc Fusion proteinBiologicJan 2029
  17. ALTUVIIIOantihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtlBiologicFeb 2035
  18. ALTUVIIIOantihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtlBiologicFeb 2035
  19. ALTUVIIIOantihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtlBiologicFeb 2035
  20. ALTUVIIIOantihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtlBiologicFeb 2035
  21. ALTUVIIIOantihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtlBiologicFeb 2035
  22. ALTUVIIIOantihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtlBiologicFeb 2035
  23. ALTUVIIIOantihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtlBiologicFeb 2035

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.

Bioverativ — patent cliffs & loss of exclusivity | CliffBio